This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Relacorilant
DrugBank Accession Number
DB14976
Background

Relacorilant is under investigation in clinical trial NCT02804750 (Study to Evaluate CORT125134 in Patients With Cushing's Syndrome).

Type
Small Molecule
Groups
Investigational
Structure
Weight
Average: 586.57
Monoisotopic: 586.141022418
Chemical Formula
C27H22F4N6O3S
Synonyms
  • CORT125134
  • Relacorilant

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
2158753C7E
CAS number
1496510-51-0
InChI Key
WANIDIGFXJFFEL-SANMLTNESA-N
InChI
InChI=1S/C27H22F4N6O3S/c1-35-15-22(14-33-35)41(39,40)36-9-7-18-11-24-17(13-34-37(24)21-4-2-20(28)3-5-21)12-26(18,16-36)25(38)23-10-19(6-8-32-23)27(29,30)31/h2-6,8,10-11,13-15H,7,9,12,16H2,1H3/t26-/m0/s1
IUPAC Name
2-[(4aR)-1-(4-fluorophenyl)-6-[(1-methyl-1H-pyrazol-4-yl)sulfonyl]-1H,4H,4aH,5H,6H,7H,8H-pyrido[3,4-f]indazole-4a-carbonyl]-4-(trifluoromethyl)pyridine
SMILES
CN1C=C(C=N1)S(=O)(=O)N1CCC2=CC3=C(C[C@@]2(C1)C(=O)C1=CC(=CC=N1)C(F)(F)F)C=NN3C1=CC=C(F)C=C1

References

General References
Not Available
ChemSpider
57617720
ChEMBL
CHEMBL4068611
ZINC
ZINC000141949519
Wikipedia
Relacorilant

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3RecruitingTreatmentAbdominal wall neoplasm / Fallopian Tube Neoplasms / Neoplasms, Ovarian1
3RecruitingTreatmentCushing's Syndrome1
3RecruitingTreatmentHypercortisolism1
3TerminatedTreatmentMetastatic Pancreatic (Ductal) Adenocarcinoma1
2Active Not RecruitingTreatmentRecurrent Fallopian Tube Carcinoma / Recurrent Ovarian Cancer / Recurrent Primary Peritoneal Carcinoma1
2CompletedTreatmentCushing's Syndrome1
2Enrolling by InvitationTreatmentCushing's Syndrome1
1CompletedBasic ScienceHealthy Subjects (HS)2
1CompletedOtherHealthy Subjects (HS)3
1CompletedOtherHealthy Subjects (HS) / Interaction Drug Food1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0164 mg/mLALOGPS
logP3.34ALOGPS
logP3.34ChemAxon
logS-4.6ALOGPS
pKa (Strongest Basic)2.37ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area102.98 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity154.09 m3·mol-1ChemAxon
Polarizability54.45 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created at May 20, 2019 14:39 / Updated at February 21, 2021 18:55